👋 Hey, let’s get into it. Moderna’s stock jumped 177% in one day because an mRNA cancer vaccine finally did something no mRNA cancer vaccine had done before: win a Phase 3 trial.

Merck and Moderna said intismeran autogene, built from each patient’s tumor mutations, improved recurrence-free and distant metastasis-free survival when added to Keytruda after melanoma surgery. It is also the first positive Phase 3 readout for any individualized neoantigen therapy.

Wall Street nearly tripled the stock. The science still needs numbers: no hazard ratios, absolute recurrence rates, or overall-survival result yet. Apparently, “topline” was enough for the trading desk.

💪 Roche Bets Up to $2.3B on Hanmi’s Muscle-Sparing Obesity Drug
Roche’s Genentech is paying Hanmi $190 million upfront for rights outside South Korea to HM17321. Milestones could take the deal’s total value to roughly $2.3 billion, with tiered royalties also possible. The Phase 1 urocortin-2 analog is designed to reduce fat while preserving or increasing lean mass, but that claim still rests on preclinical data. Hanmi will finish Phase 1 before Genentech takes over in Phase 2, where the non-GLP-1 drug could be tested alone or with incretins. If it works in humans, muscle preservation could become obesity’s next battleground. And that “if” is doing some work here.

⚠️ FDA Re-Freezes Regenxbio’s RGX-121 After Spinal MRI Findings in Five Patients
FDA placed RGX-121 back on clinical hold after expanded MRI monitoring found small spinal nodules or cystic masses in five Hunter syndrome participants treated three to six years earlier. All five remain asymptomatic and clinically stable or improving; investigators deemed the findings nonserious, radiologists consider them likely benign, and causality remains unknown. This is separate from the January hold triggered by a serious event in related program RGX-111, which FDA lifted for RGX-121 in April. Regenxbio no longer expects a near-term BLA resubmission after February’s rejection. Shares fell about 25% Monday as investors priced in yet another regulatory delay.

🇨🇳 Three China Gene-Therapy Deaths Prompt Lawmakers to Demand FDA-Audited Data
Two House lawmakers asked FDA to reject China-generated clinical data unless the trial site had undergone an FDA audit within the past year and to review U.S. approvals supported by Chinese results. The request follows three reported deaths in investigator-initiated gene or cell therapy studies, including two children. The cases involved different products, protocols, and unresolved causality, so they should not be treated as one event or evidence against all Chinese research. This remains a congressional request, not FDA policy. If adopted, companies using faster, lower-cost China trials for U.S. filings would have to rethink the playbook.

🧬 FDA Approves Ultragenyx’s Genglycos, First Therapy for Rare Glycogen Storage Disorder
Ultragenyx won accelerated approval for Genglycos, the first FDA-approved therapy for glycogen storage disease type Ia. The AAV gene therapy is indicated for patients 8 and older, alongside nutritional management, to reduce the frequent cornstarch dosing needed to prevent dangerous hypoglycemia. Approval rests on a surrogate endpoint from a 48-week Phase 3 trial, so Ultragenyx must confirm longer-term benefit after launch. At a $2.7 million list price, it is also another test of rare-disease gene therapy economics. For families whose days and nights revolve around timed cornstarch, even reducing that schedule could matter.

BioNucleus Briefing has 1,400+ combined newsletter subscriptions across email and LinkedIn, reaching scientists, founders, investors, operators, and other biotech and pharmaceutical professionals.

Sponsorship opportunities are available for companies offering tools, software, services, events, and other products relevant to the life-sciences industry.

Interested in sponsoring an upcoming issue? Reply to this email and let’s talk.

Alright, back to the newsletter.

🦠 Japan Approves GSK’s Hibsago as First Hepatitis B Functional Cure
A six-month course produced off-treatment viral control in 19% of eligible patients, although functional cure does not mean the virus is eradicated.

🏭 Genentech Puts $750M Into Oregon Device Manufacturing
The Hillsboro expansion will add prefilled-syringe and autoinjector capacity, roughly double the site’s footprint, and target commercial operations in 2031.

🏛️ Trump Nominates Heidi Overton to Lead FDA
The physician and White House health adviser still needs Senate confirmation before inheriting an agency that lost more than 3,000 employees last year.

🩸 FDA Clears Two Alzheimer’s Blood Tests in Four Days
C2N’s PrecivityAD2 and Roche’s Elecsys pTau217 assess amyloid pathology from blood in symptomatic patients, reducing dependence on PET scans and spinal taps.

🐺 Werewolf Plans to Become Ambros in $150M Reverse Merger
The proposed deal and concurrent PIPE would fund neridronate’s Phase 3 CRPS study through its 2028 readout, but both transactions still require closing.

🧬 Lilly Licenses Amplitude’s Trans-Amplifying RNA Vaccine Platform
Lilly is tapping Amplitude’s trans-amplifying RNA platform for infectious-disease vaccines, with options for two more targets and financial terms kept quiet.

🎯 FDA Gives GSK’s Jemperli Priority Review in Rectal Cancer
The filing targets untreated dMMR/MSI-H disease, where PD-1 therapy could help some patients avoid chemotherapy, radiation, and surgery if approved.

Trump’s administration has opened the childhood vaccine schedule for redesign. The paperwork published Monday, however, is the comment box, not the finished blueprint.

An August 10 executive order reorganizes federal recommendations into three buckets: routine vaccination against 11 diseases, vaccination for high-risk children, and shared clinical decision-making. It also asks states to reconsider school-entry rules and calls for measles, mumps, and rubella to be given as separate shots once those products are available domestically, preferably at separate visits. They are not currently available in the U.S.

HHS followed with a Request for Information, posted August 21 and published August 24, opening a 30-day comment period. The agency wants input on whether the categories are understandable, whether shared decision-making works, and how recommendations should be made. A separate task force has 90 days to propose changes involving timing, sequencing, standalone MMR products, adjuvants, and ongoing benefit-risk review.

None of that means the CDC schedule changed Monday. The RFI asks questions; it does not answer them. Federal recommendations also are not the same as FDA labels, insurance coverage, or state school mandates, and earlier schedule changes remain blocked by a federal court.

Still, the process matters. Recommendation categories can shape what clinicians discuss, what insurers cover, which vaccines families receive, and how manufacturers plan demand. The White House says the framework better matches peer countries, but schedules reflect different disease risks and health systems. The next battle is less about one PDF and more about who sets the evidence standard behind it.

That is how much Guardant Health was ordered to pay as part of the final judgment in a patent-infringement case brought by TwinStrand Biosciences and the University of Washington. Guardant also faces a 6% royalty on covered U.S. sales through 2033 and plans to appeal.

Here’s what biotech Redditors are talking about:

🫖 Reddit Builds a Pharma Workplace Blacklist
An r/biotech thread asked users to name the worst pharma employers, and some commenters skipped the vague posting entirely, naming specific companies while unloading complaints about leadership, meeting overload, and workplace culture. The smarter responses complicated the blacklist: experiences can vary dramatically by manager, department, geography, and whether someone knew the company as an employee or client. The tea is hot. The sample size is not.

🛩️ Where Did You Go After Leaving Biotech?
One Reddit thread produced career pivots ranging from software compliance and pilot training to aquaponic catfish farming. Some found happier lives outside biotech; others eventually came back, proving the grass is not automatically greener, though it may contain fish. Speaking personally, I know the career-pivot itch. I left biotech after seven years in life-science tools sales to launch a boba tea truck, and now run it alongside BioNucleus. It was not exactly the standard next step, but here we are. If you’re considering your own pivot into entrepreneurship, feel free to reply or connect with me on LinkedIn. I love talking through business ideas, from boba tea to biotech and everything in between.

🦠 Congo’s Ebola Death Toll Reaches 2,642
The Bundibugyo outbreak recorded more than 300 deaths last week alone, while conflict, attacks on health workers, and scarce funding keep slowing containment.

🩸 FDA Clears First Fully Autonomous Blood-Draw Robot
Vitestro’s Aletta received De Novo authorization to find veins and collect routine samples autonomously under supervision, creating a pathway for similar devices…and nightmare fuel for those who hate needles.

🧠 Brain Organoids Survive Nearly Six Years in the Lab
Across 110 organoids and more than 424,000 cells, molecular maturation followed a human-like developmental clock. The organoids are growing up so fast.

🤖 AI Antibody Models Ace the Homework, Flunk the Surprise Test
In a blinded 511-antibody benchmark, several AI teams excelled with abundant training data, but nearly every ranking model lost to random clone selection.

🍽️ Pheast Bets Transparency Can Outrun the Competition
Pheast Therapeutics is staying unusually open about its pipeline even after a rival reached the clinic first with another CD24 antibody. Its lead program, PHST001, blocks a macrophage “don’t eat me” signal that tumors use to evade immune attack and is now in Phase 1 testing for advanced solid tumors. Early safety and activity observations remain preliminary, with a fuller readout expected in 2027. Pheast’s bet is that explaining the science can attract investors, clinicians, and partners faster than it educates competitors.

🔄 August 25, 1900: The Scientist Behind Biology’s Most Famous Cycle Is Born
Hans Adolf Krebs was born in Hildesheim, Germany, on this day in 1900. Forced from his Freiburg post under Nazi anti-Jewish policies, he continued his career in Britain and described the citric acid cycle in 1937. The pathway showed how cells extract usable energy from nutrients and earned Krebs half of the 1953 Nobel Prize in Physiology or Medicine, with Fritz Lipmann receiving the other half. His name has since condemned generations of biology students to memorizing an intimidating circle of arrows.

I’m not sure what will keep me up more tonight: thinking about a robot taking my blood or having flashbacks to showing up for biology class only to find a pop quiz on the Krebs cycle.

Honestly, I’d probably take the robot. At least it only has to find one vein, not memorize an entire circle of arrows.

That’s all for today. See you Thursday for the next issue. 👋

✍️ Today’s email was brought to you by Josh Martin. Connect with me on LinkedIn.

If you’re enjoying BioNucleus, share it with a friend or coworker who’d get value from it. We’re a small operation, and every share makes a bigger difference than you think.

Was this email forwarded to you? Sign up here 👇

Subscribe for free

Follow us on social and stay one step ahead